Literature DB >> 19933906

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.

Elizabeth R Gerstner1, Matthew P Frosch, Tracy T Batchelor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19933906     DOI： 10.1200/JCO.2009.25.0233

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  50 in total

1.  Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

Authors:  John R Hesselink; Matthew J Barkovich; Tyler M Seibert; Nikdokht Farid; Karra A Muller; Kevin T Murphy; Santosh Kesari
Journal:  CNS Oncol       Date:  2014

Review 2.  Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.

Authors:  Wolfgang Wick; Antje Wick; Markus Weiler; Michael Weller
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

Review 3.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

4.  Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.

Authors:  S Mong; B M Ellingson; P L Nghiemphu; H J Kim; L Mirsadraei; A Lai; W Yong; T M Zaw; T F Cloughesy; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

Review 5.  "Dazed and diffused": making sense of diffusion abnormalities in neurologic pathologies.

Authors:  K M O'Connor; G Barest; T Moritani; O Sakai; A Mian
Journal:  Br J Radiol       Date:  2013-10-28       Impact factor: 3.039

6.  CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.

Authors:  J Dawn Waters; Carlos Sanchez; Ayguen Sahin; Diahnn Futalan; David D Gonda; Justin K Scheer; Johnny Akers; Kamalakannan Palanichamy; Peter Waterman; Arnab Chakravarti; Ralph Weissleder; Brent Morse; Nick Marsh; Eric Furfine; Clark C Chen; Irvith Carvajal; Bob S Carter
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

7.  Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.

Authors:  Carrie R McDonald; Rachel L Delfanti; Anitha P Krishnan; Kelly M Leyden; Jona A Hattangadi-Gluth; Tyler M Seibert; Roshan Karunamuni; Pia Elbe; Joshua M Kuperman; Hauke Bartsch; David E Piccioni; Nathan S White; Anders M Dale; Nikdokht Farid
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

8.  Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients.

Authors:  David Cachia; Nabil A Elshafeey; Carlos Kamiya-Matsuoka; Masumeh Hatami; Kristin D Alfaro-Munoz; Jacob J Mandel; Rivka Colen; John F DeGroot
Journal:  J Neurooncol       Date:  2017-07-12       Impact factor: 4.130

Review 9.  An Update on the Approach to the Imaging of Brain Tumors.

Authors:  Katherine M Mullen; Raymond Y Huang
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

10.  Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.

Authors:  Rifaquat Rahman; Alhafidz Hamdan; Rebecca Zweifler; Han Jiang; Andrew D Norden; David A Reardon; Srinivasan Mukundan; Patrick Y Wen; Raymond Y Huang
Journal:  J Neurooncol       Date:  2014-05-08       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.